Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29840591 | 0.96 | USP2 (0.53) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL840882 | 0.86 | USP2 (0.50) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL12339103 | 0.85 | USP2 (0.43) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL17036956 | 0.85 | USP2 (0.43) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL5070659 | 0.83 | — | — | |
| SCHEMBL10656088 | 0.81 | — | — | |
| SCHEMBL14962984 | 0.81 | USP2 (0.40) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL14962983 | 0.79 | KDM4E (0.39) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL5873343 | 0.78 | — | — | |
| Ethane Dimethane Sulfonate SCHEMBL1336145 | 0.77 | USP2 (0.75) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| US-12628858-B2 | Therapy for colorectal and small intestine cancers | CORNELL UNIVERSITY (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | disclosed |
| EP-3696901-B1 | LITHIUM SECONDARY BATTERY | SAMSUNG SDI CO LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| US-12212005-B2 | Lithium battery with improved penetration characteristics and manufacturing method therefor | SAMSUNG SDI CO., LTD. (KR) | 2025-01-28 | — | — | US | disclosed |
| US-12180551-B2 | Method of using biomarkers and clinical variables for predicting chemotherapy benefit | MYRIAD INTERNATIONAL GMBH (DE) | 2024-12-31 | — | — | US | disclosed |
| CN-117996188-A | Novel additive, electrolyte and lithium ion battery | 万向一二三股份公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-114539256-B | Tricyclic compounds and medical uses thereof | 上海拓界生物医药科技有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230343965-A1 | SECONDARY BATTERY | MURATA MANUFACTURING CO (JP) | 2023-10-26 | — | — | US | disclosed |
| US-4393001-A | ANTIBIOTICS, BACTERICIDES | PFIZER INC. (US) | 1983-07-12 | — | — | US | disclosed |
| EP-0074783-A1 | Beta-lactamase inhibiting 2-beta-substituted-2-alpha-methyl-(5R) penam-3-alpha-carboxylic acid 1,1-dioxides and intermediates therefor | PFIZER INC. (US) | 1983-03-23 | — | — | EP | disclosed |
| US-4377524-A | Bis-esters of methanediol with penicillins and penicillanic acid 1,1-dioxide | PFIZER INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4364957-A | Bis-esters of alkanediols as antibacterial agents | PFIZER INC. (US) | 1982-12-21 | — | — | US | disclosed |
| US-4356174-A | ANTIBIOTIC | PFIZER INC. (US) | 1982-10-26 | — | — | US | disclosed |
| EP-0061274-A1 | Process and intermediates for production of 1,1-dioxopenicillanoyloxymethyl 6-(2-amino-2-phenylacetamido)penicillanates | PFIZER INC. (US) | 1982-09-29 | — | — | EP | disclosed |
| EP-0061315-A1 | Process for preparing penicillanic acid 1,1-dioxide derivatives and certain intermediates useful therein | PFIZER INC. (US) | 1982-09-29 | — | — | EP | disclosed |
| EP-0059046-A1 | Bis-esters of alkanediols, pharmaceutical compositions thereof and intermediates therefor | PFIZER INC. (US) | 1982-09-01 | — | — | EP | disclosed |
| US-4244951-A | Bis-esters of methanediol with penicillins and penicillanic acid 1,1-dioxide | PFIZER INC. (US) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12628858-B2 | Therapy for colorectal and small intestine cancers | FABP2, PKN2, APC | USP2 3646/4885TSHR 3109/4885KDM4E 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.